PGI26 Resource Utilization and Costs Associated with Diverticulitis Inpatient Admissions: An Analysis of the Economic Burden of Diverticulitis  by Spiegel, B. et al.
cost-effectiveness ratio for the treatment of CDAD with fidaxomicin, metronida-
zole, and vancomycin were $16,903.12, $20,229.74, and $17,386.62 per clinical cure,
respectively. Metronidazole was dominated by vancomycin. According to the
CEAF, vancomycin has a cost-effectiveness probability of 0.4 at a WTP of $0/addi-
tional cure. At a WTP $22,000/additional cure, however,fidaxomicin was more
cost-effective. CONCLUSIONS: Fidaxomicin is cost-effective when the WTP is
$22,000/additional cure. At a WTP $22,000/additional cure, however, vancomy-
cin is more cost-effective. Metronidazole does not appear to be a cost-effective
strategy for CDAD when compared to fidaxomicin and vancomycin.
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OBJECTIVES: Evaluate the cost-effectiveness of proton pump inhibitors (PPIs) avail-
able in the public health sector in Mexico for the treatment of gastroesophageal
Reflux Disease (GERD) graded C to D according to Los Angeles classification.
METHODS: A decision-analytic model was developed to estimate costs and effects
for each PPI (esomeprazole 40mg [ESO]; omeprazole 20mg [OME]; lansoprazole
30mg [LAN]; pantoprazole 40mg [PAN]). It was established a 4 weeks treatment
period, after it the patient heal rate was evaluated, and if the prescribed dose was
increased ormaintained. The relapse rate was also taken in account. The effective-
nessmeasurewas the proportion of patientswith endoscopic healing of the lesions
of the disease, using published data on effectiveness (healing and relapse rates) in
GERD. To estimate the resources consumption for diagnosis and treatment at dif-
ferent stages physician survey was carried out in August 2011 involving 7 gastro-
enterologists. Drug costs and health information comes from public health insti-
tutions. All costs were calculated in 2011 US Dollars (exchange rate in december
2011 1USD13.94 mexican pesos, source: http://www.banxico.org.mx). Univariate
sensitivity analysis was performed for the key variables of the model. RESULTS:
ESO was most effective than others comparators and resulted the alternative with
less unitary average total cost. ESO had a 99.6% heal rate and at a cost of $986.59
USD , OME had a 97% heal rate and a cost of $1140.77, PAN had a 94%heal rate and
a cost of $1456.74; LAN had a 98% of heal rate $1486.71. ESO is a dominant option
and cost saving compared to the alternatives. Deterministic probabilistic sensitiv-
ity analysis showed that the findings are robust.CONCLUSIONS:With these results
we can conclude that ESO is the dominant alternative, considering the total direct
medical costs. Esomeprazole provide better clinical efficacy at lower cost.
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OBJECTIVES: Many patients infected with HCV genotype 1 (HCVG1) have not re-
sponded to therapy with peginterferon plus ribavirin (PR). In May 2011, the Brazil-
ian Ministry of Health released guidelines for the treatment of patients with hep-
atitis C infection where the recommended retreatment regimen for HCVG1
infected patients is standard dose PR for 72 weeks. The extended compared to
standard treatment duration improves sustained virologic response (SVR) rates in
these patients. The aim of this study is to assess the cost effectiveness of this
improved efficacy.METHODS:We developed a Markov model to describe the clin-
ical history of HCV infection inwhich cohorts of HCVG1 previously treated patients
who didn’t achieve sustained response receives standard dose PR for 48 or 72
weeks. Patients with detectable HCV RNA level at week 12 have their treatment
interrupted. The patients are followed for their expected lifetime. The reference
patient is 30-year-old with CHC without cirrhosis. The SVRs to 48 and 72 weeks
cohorts came from RESPOND 2 and Jenssen DM et al, 2009 studies, respectively.
Quality of life for each health state was based on literature. Costs for each health
state were based on three Delphi panels (hepatologists, intensivists and oncolo-
gists). Costs in 2011 Brazilian Reais (BRL) and benefits were discounted at 3%.
RESULTS: The 72 weeks extended treatment increases life expectancy by 0.62 year
and quality adjusted life years (QALY) by 0.95 year compared to standard treament.
The incremental cost per life year gained is 3.423 BRL and the incremental cost per
QALY is 2.232 BRL. CONCLUSIONS: New drugs in development may further im-
prove retreatment options, but until then the Brazilian Ministry of Health recom-
mendation to extend the treatment to 72 weeks in HCV genotype 1 previously
treated patients who didn’t achieve sustained response is cost-effective as com-
pared with standard 48 weeks duration.
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OBJECTIVES: In patients with chronic infection with hepatitis C virus (HCV) geno-
type 1 who do not have a sustained response to the standard therapy with pegin-
terferon-ribavirin (PR) the treatment with the combination of boceprevir plus
peginterferon alfa/ribavirin (BPR) has been shown to produce a higher rate of sus-
tained virological response (SVR) than the retreatment with PR. The aim of this
study is to assess the cost effectiveness of this improved efficacy. METHODS: We
developed a Markov model to describe the clinical history of HCV infection in
which HCV genotype 1 previously treated patients who did not achieve sustained
response receives PR for 4 weeks and subsequently, one cohort (A) receives PR for
44 weeks and another cohort (B) receives BPR for 32 weeks and, in this cohort (B),
those patients with a detectable HCV RNA level at week 8 receives PR for an addi-
tional 12 weeks. All patients are followed for their expected lifetime. The reference
patient is 30-year-old with CHC without cirrhosis. The SVRs to BPR and PR cohorts
came from RESPOND 2 study. Quality of life for each health state was based on
literature. Costs for each health state were based on three Delphi panels, one with
hepatologists, one with intensivists and another with oncologists. Costs in 2011
Brazilian Reais and benefitswere discounted at 3%.RESULTS:The combination BPR
increases life expectancy by 2.75 years and quality adjusted life years (QALY) by
4.19 years compared to PR. The incremental cost per life year gained is 7.992 Bra-
zilian Reais and the incremental cost per QALY is 5.244 Brazilian Reais.
CONCLUSIONS: In Brazil, boceprevir plus peginterferon alfa/ribavirin is a cost-
effective therapy, for the treatment of previously treated patients with HCV geno-
type 1 infection as compared with peginterferon alfa/ribavirin alone.
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OBJECTIVES: In previously untreated adults with hepatitis C virus (HCV) genotype
1 infection the combination of boceprevir plus peginterferon alfa/ribavirin (BPR)
has been shown to produce a higher rate of sustained virological response (SVR)
than peginterferon alfa/ribavirin (PR). The aim of this study is to assess the cost
effectiveness of this improved efficacy.METHODS:We developed a Markov model
to describe the clinical history of CHC inwhichHCV genotype 1 patients receives PR
for 4 weeks and subsequently one cohort (A) receives PR for 44 weeks and another
cohort (B) receives BPR for 24 weeks and, in this cohort (B), those patients with a
detectable HCV RNA level between weeks 8 and 24 receives PR for an additional 20
weeks. All patients are followed for their expected lifetime. The reference patient is
30-year-oldwith CHCwithout cirrhosis. The SVRs to BPR and PR cohorts came from
SPRINT 2 study. Quality of life for each health state was based on literature. Costs
for each health state were based on three Delphi panels, one with hepatologists,
one with intensivists and another with oncologists. Costs in 2011 Brazilian Reais
and benefitswere discounted at 3%.RESULTS:BPR increases life expectancy by 2.07
years and quality adjusted life years (QALY) by 3.15 years compared to PR. The
incremental cost per life year gained is 11.394 Brazilian Reais and the incremental
cost per QALY is 7.494 Brazilian Reais. CONCLUSIONS: In Brazil, boceprevir plus
peginterferon alfa/ribavirin is a cost-effective therapy, for treatment of previously
untreated adults with HCV genotype 1 compared with peginterferon alfa/ribavirin.
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OBJECTIVES: Although the incidence of diverticulitis (DV) is increasing and DV
attacks are common, resource utilization associated with DV inpatient admissions
has not been extensively analyzed. To better understand the economic burden of
DV, detailed chart reviews were performed to quantitate resource utilization in a
random sample of DV admissions at a VA medical center from 1996 to 2010.
METHODS:We examined clinical variables and resource counts including surgical
and gastrointestinal consults, computerized tomography scans, laboratory values,
interventional radiology (IR) procedures, surgeries, medications, length of stay
(LOS), and intensive care unit (ICU), monitored bed, and ward days. Resource mi-
cro-costing from a third-party payer perspective was performed based on 2010
Current Procedural Terminology fees and the Red Book. Aggregate costs for initial
and subsequent attacks were compared and cost predictors were identified by
multivariable regression. RESULTS:Among 240 patients (age, 66.6 years; 95%male)
with complete data, themean (standard deviation [SD]) LOS per admissionwas 10.4
(20.66) days with a mean (SD) of 1.2 (4.19), 1.7 (4.35), and 6.0 (9.03) days in ICU,
monitored, and ward beds, respectively. Patients’ mean maximum temperature
(Tmax) and white blood cell count were 99.7° F and 14.7K, respectively; 29% re-
ceived surgery and 11% received IR procedures. Mean (SD) and median costs per
admission were $8496 ($14,002) and $4,080, respectively. An upward trend in me-
dian cost was observed for first, second, and subsequent admissions ($3707, $4722,
and $6143 per stay, respectively; not statistically significant). LOS was indepen-
dently associated with increasing patient age, higher Tmax, and receipt of surgery
(P0.0001 for all; R2 47%). CONCLUSIONS: These findings describe the economic
burden of DV and identify clinical parameters that may be associated with in-
creased resource utilization. Future studies will be needed to determine if these
benchmarks are consistent in other and/or larger populations.
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